[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"community-acquired-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:community-acquired-infections":84},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,71,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100592700","noninvasive-support-methods-for-acute-respiratory-failure-of-community-acquired-pneumonia-100592700",false,"NCT06996834","Noninvasive Support Methods for Acute Respiratory Failure of Community-acquired Pneumonia","A Randomized Controlled Trial of High-Velocity Nasal Insufflation (HVNI) Versus Noninvasive Ventilation (NIV) for Acute Respiratory Failure of Community-Acquired Pneumonia (CAP).","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Clinical and radiographic diagnosis of CAP\n* Respiratory failure using partial pressure of oxygen (PaO₂) and fraction of inspired oxygen (FiO₂) is defined by a partial pressure of oxygen\u002Ffraction of inspired oxygen ratio (PaO₂\u002FFiO₂) ≤ 300 mmHg or a respiratory rate (RR) ≥ 25\u002Fmin\n* Informed consent obtained\n\nExclusion Criteria:\n\n* Hemodynamic instability requiring vasopressors\n* Altered mental status Glasgow Coma Scale (GCS \\\u003C 13)\n* Contraindication to NIV or HVNI (facial trauma, recent upper airway surgery)\n* Do-Not-Intubate (DNI) order","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","This randomized controlled trial aims to compare the efficacy and safety of high-velocity nasal insufflation (HVNI) versus standard noninvasive ventilation (NIV) in adult patients experiencing acute exacerbations of community-acquired pneumonia (CAP) accompanied by hypoxemic respiratory failure. The primary focus is on assessing treatment failure within 48 hours, defined as the need for intubation or death. Secondary outcomes include evaluations of gas exchange parameters, patient comfort levels, duration of ICU stay, and 28-day mortality rates.",[26,27],"Community-acquired Pneumonia","Community-Acquired Infections",[29,30,31],"CAP","NIV","HVNI","RECRUITING","2026-04-26",{"date":35,"type":36},"2026-04-30","ACTUAL",{"date":38,"type":36},"2025-07-01",{"date":40,"type":20},"2026-11-01",{"name":42,"class":43},"Assiut University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100524037","integrated-clinical-decision-support-for-empiric-antibiotic-selection-in-sepsis-100524037","NCT06103500","Integrated Clinical Decision Support for Empiric Antibiotic Selection in Sepsis","Integrated Clinical Decision Support for Empiric Antibiotic Selection in Sepsis: A Cluster Randomized Cross-Over Trial (IDEAS-CRXO)","IDEAS-CRXO","Inclusion Criteria:\n\n1. Admitted\n2. Age \\>18 years old\n3. Newly started (within 24 hours of assessment for eligibility) on at least one of the following antibiotic(s):\n\n   I. Vancomycin IV II. Linezolid III. Daptomycin IV. Clindamycin V. Cefazolin VI. Cloxacillin VII. Ceftriaxone VIII. Ceftazidime IX. Piperacillin-Tazobactam X. Meropenem (or Imipenem or Ertapenem) XI. Ciprofloxacin\n4. Blood cultures ordered (within 12 hours before or after initiation of index antibiotics).\n\nOverall Exclusion:\n\n1. Pregnancy\u002Fbreastfeeding\n2. Documented end-of-life (palliative) care and are\u002Fwill not be receiving ongoing antibiotic treatment.\n3. Already enrolled in the trial.\n4. Positive clinical culture results (those with speciation) for the index infection (within 72 hours) already available prior to assessment. Blood cultures with any Gram-positives will be an exclusion. Other cultures that are positive with a Gram-stain result but not speciation will not be an exclusion criteria.\n5. Explanatory molecular test (e.g. legionella urinary antigen test, sars-cov-2 testing) within 72 hours prior to assessment.\n6. Receipt of antimicrobials (not chronic suppression or prophylaxis) in the prior 24-72 hours (except if started in the outpatient setting or ED prior to admission in the 24-72 hours).\n7. The index prescription is a continuation of an antibiotic given for suppressive chronic therapy or long-standing treatment of an established infection.\n8. Index antibiotics are peri-operative only or ordered for \\\u003C24 hours.\n9. Cystic fibrosis.\n10. Known to be enrolled in a trial that dictates antimicrobial selection.\n11. Not eligible for any of the algorithms.",{"count":54,"type":20},1440,[23],"As antibiotic resistance increases globally, it becomes more difficult to select empiric antibiotic therapy, particularly in patients with sepsis who stand to benefit from early adequate treatment. In particular it is difficult for clinicians to balance antibiotic stewardship principles (the need to avoid unnecessary prescribing of antibiotics that have an excessively broad spectrum of activity that favour resistance development) and under treatment. The integration of multiple risk variables for resistance are hard for clinicians to translate into clinical action, and is seemingly at odds with the natural inclination to provide heuristic\u002Femotion-based antibiotic selection. The inappropriate treatment of sepsis is not uniformly too broad, or too narrow, and there is a need to optimize and tailor selection of antibiotic therapy to each patient, such that those that are at risk for resistant organisms receive broad therapy, and those that are not at risk, receive narrower antibiotic agents.\n\nClinicians need support picking the right antibiotic for each patient, and from this they can potentially drive reduction of unnecessarily broad antibiotic prescribing while preserving adequacy of treatment. Individualized clinical prediction models and decision support interventions are promising approaches that meet these needs by improving the classification of patient risk for antibiotic resistant or susceptible infections in sepsis. Unfortunately, few have been validated in the clinical setting and larger rigorous studies are needed to provide the evidence to support broader clinical adoption.\n\nThe investigators will perform a cluster randomized cross-over trial of an individualized antibiotic prescribing decision support intervention for providers treating hospitalized patients with suspected sepsis. The aim of this trial is to determine whether a stewardship led clinical decision support intervention can improve antibiotic de-escalation in patients with sepsis while maintaining or improving adequacy of antibiotic coverage. This decision support intervention will be based on a combination of proven decision heuristics (for Gram-positive organisms) and modelled predicted susceptibilities (for Gram-negative organisms) that are individualized to the patient. The primary outcome will be the proportion of patients de-escalated from their initial empiric regimen at 48 hours.",[58,59,27,60],"Sepsis","Bacterial Infections","Hospital Infection","2025-03-13",{"date":63,"type":36},"2025-03-17",{"date":65,"type":36},"2024-05-21",{"date":67,"type":20},"2025-10",{"name":69,"class":43},"Ottawa Hospital Research Institute",3,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":44},"100570387","clinical-and-ecological-impact-of-a-primary-care-antimicrobial-stewardship-program-based-on-telematic-educational-interviews-telmaco-trial-100570387","NCT06706583","Clinical and Ecological Impact of a Primary Care Antimicrobial Stewardship Program Based on Telematic Educational Interviews (TELÉMACO Trial)","Clinical and Ecological Impact of a Primary Care Antimicrobial Stewardship Program Based on Telematic Educational Interviews. A Cluster Randomized Clinical Trial (TELÉMACO Trial)","TELÉMACO","Inclusion criteria:\n\na) Primary Care centres within the reference area of the University Hospital Virgen del Rocío.\n\nExclusion criteria:\n\n1. Emergency departments.\n2. Odontology offices.\n3. DDD per Health centre less than 5.78",{"count":80,"type":20},30,[23],"Brief Summary: Open-label, cluster randomized, multicenter clinical trial to evaluate the clinical and ecological impact of a Primary Care ASP based on telematic educational interviews.",[84],"Community Acquired Infections",[86,87,88,89],"Antimicrobial Stewardship Program (ASP)","Primary Care","Telemedicine","PIRASOA","2024-11-22",{"date":92,"type":36},"2024-11-26",{"date":94,"type":20},"2024-12-01",{"date":96,"type":20},"2026-03-31",{"name":98,"class":43},"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":44},"100563245","cohort-study-on-the-treatment-of-severe-pneumonia-with-traditional-chinese-medicine-100563245","NCT06613659","Cohort Study on the Treatment of Severe Pneumonia with Traditional Chinese Medicine","Cohort Study on the Efficacy of Traditional Chinese Medicine Syndrome Differentiation Scheme in Adjuvant Treatment of Severe Pneumonia Based on the Real World","Inclusion Criteria:\n\n* It met the diagnostic criteria of severe pneumonia;\n* Age ≥ 18 years old, regardless of gender.\n* Voluntary treatment.\n* Sign the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or lactating women;\n* Patients with mental illness who are unable to cooperate or unwilling to cooperate with follow-up;\n* Those who are participating in clinical trials of other drugs;\n* Known allergic to therapeutic drugs.",{"count":107,"type":20},1016,"OBSERVATIONAL","This is a multicenter, prospective cohort study, with syndrome differentiation and treatment of traditional Chinese medicine as the exposure factor. Patients using syndrome differentiation of traditional Chinese medicine combined with conventional treatment of Western medicine are classified as the treatment cohort of Integrated Chinese and Western medicine, and patients using conventional treatment of Western medicine only are classified as the treatment cohort of Western medicine",[27],[27,112,113],"Traditional Chinese Medicine","Cohort study","NOT_YET_RECRUITING","2024-09-25",{"date":117,"type":36},"2024-09-26",{"date":119,"type":20},"2024-09-20",{"date":121,"type":20},"2027-10-30",{"name":123,"class":43},"Henan University of Traditional Chinese Medicine"]